Click on headlines below to download research
New year, renewed focus
ASIT biotech | 17/01/2019
ASIT has announced renewed focus on its most advanced product, gp-ASIT+ for grass pollen allergies, which coincides with some changes in senior management.…
The 82-centre gp-ASIT+ Phase III study launches
ASIT biotech | 20/11/2018
In a well-received announcement, ASIT has launched the confirmatory Phase III study on gp-ASIT+ for grass pollen allergy with study centres in six European…
Setting the stage for the confirmatory Phase III
ASIT biotech | 27/09/2018
ASIT Biotech’s H1 results statement included an outline of its preparations for the confirmatory Phase III study of its short-course gp-ASIT+ for…
All go on Phase III
ASIT biotech | 16/07/2018
On July 11 ASIT biotech raised €12m in commitments in a heavily oversubscribed convertible bond placement. In raising this additional capital, ASIT…
Executive interview – ASIT Biotech
Executive interview – ASIT Biotech | 16/07/2018
ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase…
New generation of allergy immunotherapy
ASIT biotech | 29/05/2018
ASIT biotech is an allergy immunotherapy (AIT) discovery and development company leveraging its proprietary ASIT+ platform. The lead product, gp-ASIT+…